ORAMED PHARMACEUTICALS INC. (ORMP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 10.73M USD | Liabilities, Current |
| Cash and equivalents | 15.24M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 846.00K USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.73M | $15.24M | $846.00K | (m) | (m) | (m) |
| 2026-03-31 | (m) | $10.56M | $13.20M | $4.96M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $19.09M | $45.95M | $5.42M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.12M | $52.18M | $4.96M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $3.69M | $15.80M | $1.75M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $5.49M | (m) | $3.69M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $5.68M | (m) | $3.44M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $5.27M | (m) | $646.00K | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.73M | (m) | $2.35M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $33.56M | $18.58M | $2.03M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $53.21M | $9.05M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $78.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.07M | (m) | $943.00K | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.97M | (m) | $2.27M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.75M | (m) | $3.74M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.53M | (m) | $5.23M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.42M | (m) | $6.63M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $6.32M | (m) | $7.28M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $7.37M | (m) | $7.75M | (m) | (m) | (m) |
| 2021-11-30 | (m) | $7.66M | $31.88M | $7.57M | (m) | (m) | (m) |
| 2021-08-31 | (m) | $6.68M | $77.25M | $5.85M | (m) | (m) | (m) |
| 2021-05-31 | (m) | $5.75M | $57.41M | $7.21M | (m) | (m) | (m) |
| 2021-02-28 | (m) | $5.93M | $33.80M | $9.87M | (m) | (m) | (m) |
| 2020-11-30 | (m) | $5.74M | $14.93M | $8.82M | (m) | (m) | (m) |
| 2020-08-31 | (m) | $4.54M | $19.30M | $9.54M | (m) | (m) | (m) |
| 2020-05-31 | (m) | $4.13M | $9.31M | $8.34M | (m) | (m) | (m) |
| 2020-02-29 | (m) | $5.16M | $5.93M | $5.70M | (m) | (m) | (m) |
| 2019-11-30 | (m) | $4.64M | $3.17M | $3.21M | (m) | (m) | (m) |
| 2019-08-31 | (m) | $5.31M | $3.33M | $3.70M | (m) | (m) | (m) |
| 2019-05-31 | (m) | $5.22M | $3.95M | $4.22M | (m) | (m) | (m) |
| 2019-02-28 | (m) | $5.10M | $3.43M | $5.47M | (m) | (m) | (m) |
| 2018-11-30 | (m) | $4.16M | $3.86M | $5.14M | (m) | (m) | (m) |
| 2018-08-31 | (m) | $4.55M | $5.00M | $4.59M | (m) | (m) | (m) |
| 2018-05-31 | (m) | $5.64M | $3.67M | $3.71M | (m) | (m) | (m) |
| 2018-02-28 | (m) | $4.72M | $3.29M | $3.23M | (m) | (m) | (m) |
| 2017-11-30 | (m) | $5.12M | $1.26M | $2.72M | (m) | (m) | (m) |
| 2017-08-31 | (m) | $5.17M | $3.97M | $2.86M | (m) | (m) | (m) |
| 2017-05-31 | (m) | $5.04M | $1.73M | $3.07M | (m) | (m) | (m) |
| 2017-02-28 | (m) | $4.93M | $1.45M | $3.61M | (m) | (m) | (m) |
| 2016-11-30 | (m) | $4.73M | $2.29M | $3.69M | (m) | (m) | (m) |
| 2016-08-31 | (m) | $3.62M | $3.91M | $2.85M | (m) | (m) | (m) |
| 2016-05-31 | (m) | $1.34M | $3.30M | $3.36M | (m) | (m) | (m) |
| 2016-02-29 | (m) | $1.52M | $3.23M | $2.08M | (m) | (m) | (m) |
| 2015-11-30 | (m) | $1.30M | $1.95M | $1.98M | (m) | (m) | (m) |
| 2015-08-31 | (m) | $1.49M | $3.21M | $2.09M | (m) | (m) | (m) |
| 2015-05-31 | (m) | $765.00K | $3.85M | $758.00K | (m) | (m) | (m) |
| 2015-02-28 | (m) | $605.00K | $1.10M | $695.00K | (m) | (m) | (m) |
| 2014-11-30 | (m) | $827.00K | $6.66M | $688.00K | (m) | (m) | (m) |
| 2014-08-31 | (m) | $973.00K | $1.76M | $1.05M | (m) | (m) | (m) |
| 2014-05-31 | (m) | $495.04K | $2.47M | $1.06M | (m) | (m) | (m) |
| 2014-02-28 | (m) | $349.82K | $3.25M | $1.46M | (m) | (m) | (m) |
| 2013-11-30 | (m) | $668.53K | $1.37M | $962.39K | (m) | (m) | (m) |
| 2013-08-31 | (m) | $498.19K | $2.27M | $956.38K | (m) | (m) | (m) |
| 2013-05-31 | $2.24M | $446.02K | $1.10M | $803.37K | $333.72K | (m) | 5.03× |
| 2013-02-28 | $3.47M | $469.39K | $2.04M | $987.35K | $439.75K | (m) | 7.39× |
| 2012-11-30 | $6.67M | $334.55K | $5.53M | $1.06M | $75.95K | (m) | 19.94× |
| 2012-08-31 | $4.72M | $644.42K | $4.43M | $200.31K | $87.69K | (m) | 7.32× |
| 2012-05-31 | $1.79M | $355.86K | $1.30M | $357.32K | $135.40K | (m) | 5.04× |
| 2012-02-29 | $2.21M | $582.16K | $1.82M | $341.45K | $46.67K | (m) | 3.80× |
| 2011-11-30 | $1.96M | $424.37K | $1.50M | $380.36K | $86.00K | (m) | 4.62× |
| 2011-08-31 | $2.44M | $441.29K | $1.51M | $384.56K | $542.89K | (m) | 5.53× |
| 2011-05-31 | (m) | (m) | $1.92M | (m) | (m) | (m) | (m) |
| 2011-02-28 | (m) | (m) | $1.93M | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | $1.10M | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | $1.20M | (m) | (m) | (m) | (m) |
| 2009-08-31 | (m) | (m) | $1.72M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |